

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

<hr/>		
<b>IN RE: SUBOXONE (BUPRENORPHINE</b>	<b>:</b>	<b>MDL NO. 2445</b>
<b>HYDROCHLORIDE AND NALAXONE)</b>	<b>:</b>	<b>13-MD-2445</b>
<b>ANTITRUST LITIGATION</b>	<b>:</b>	
<hr/>	<b>:</b>	
	<b>:</b>	
<b>THIS DOCUMENT APPLIES TO:</b>	<b>:</b>	
	<b>:</b>	
<i>Amneal Pharmaceuticals LLC v.</i>	<b>:</b>	
<i>Indivior Inc. et al., 16-cv-563</i>	<b>:</b>	
<hr/>	<b>:</b>	

**ORDER**

**AND NOW**, this 4<sup>th</sup> day of January, 2017, upon consideration of “Indivior, Inc.’s Partial Motion to Dismiss Amneal’s Complaint” (Doc. No. 10), the response, reply and sur-reply thereto, following oral argument, and in accordance with accompanying Memorandum Opinion, it is hereby **ORDERED** that Indivior’s motion to dismiss is **GRANTED** in part and **DENIED** in part as follows:

- Amneal’s standalone delay claim relating to the REMS/SSRS process is **DISMISSED**.
- Amneal’s Lanham Act False Advertising claim (Count 3) is **DISMISSED**.
- All claims against Reckitt Benckiser Pharmaceuticals Inc. and Indivior PLC are **DISMISSED**.
- Amneal may file an amended complaint to attempt to cure the deficiencies in its Lanham Act claim within thirty (30) days of the date of this Order.

**BY THE COURT:**

/s/ Mitchell S. Goldberg

---

**MITCHELL S. GOLDBERG, J.**